Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clostridium butyricum + bifidobacterium infantis (Shenzhen Children's Hospital)
- Development stage
- Unknown
- Lead developer
- Shenzhen Children's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A combination of two probiotic strains, *Clostridium butyricum* and *Bifidobacterium infantis*, used primarily for the treatment of gastrointestinal disorders such as antibiotic-associated diarrhea (AAD). *Clostridium butyricum* is a gram-positive, spore-forming anaerobe that produces butyric acid, a short-chain fatty acid that provides energy to colonocytes, maintains the integrity of the intestinal mucosa, and inhibits the growth of pathogenic bacteria like *Clostridium difficile*. *Bifidobacterium infantis* is a key colonizer of the infant gut that aids in the digestion of complex carbohydrates and supports the development of the immune system. Together, they restore the balance of the intestinal microflora, which is often disrupted by antibiotic therapy. This combination has been notably studied and utilized by Shenzhen City Children Hospital for pediatric AAD management.
- Brand names
- Changleyi
- Other names
- Clostridium Butyricum and Bifidobacterium Infantis Live Combined PowderBifidobacterium and Clostridium Butyricum Live Combined Powder
Beyond the preview
Go deeper on clostridium butyricum + bifidobacterium infantis (Shenzhen Children's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clostridium butyricum + bifidobacterium infantis (Shenzhen Children's Hospital).